Acasti Pharma Inc. (ACST) |
| 3.37 0.13 (4.01%) 10-25 16:00 |
| Open: | 3.4268 |
| High: | 3.448 |
| Low: | 3.2 |
| Volume: | 27,682 |
| Market Cap: | 34(M) |
| PE Ratio: | -2.36 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 4.97 |
| Resistance 1: | 4.22 |
| Pivot price: | 3.91 |
| Support 1: | 3.01 |
| Support 2: | 2.50 |
| 52w High: | 3.6 |
| 52w Low: | 1.98 |
Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.
Financials
| EPS | -1.430 |
| Book Value | 5.860 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -11.6 |
| Return on Equity (ttm) | -18.6 |
Company news
Tue, 06 Jan 2026
Acasti Pharma (CVE:ACST) Shares Up 1.8% – Here’s Why - Defense World
Fri, 25 Oct 2024
Acasti Announces Corporate Name Change to Grace Therapeutics, Inc. - GlobeNewswire
Wed, 10 Jul 2024
Is Acasti Pharma (ACST) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Tue, 24 Jan 2023
Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31 - FinancialContent
Wed, 12 May 2021
Press Telegram - FinancialContent
Fri, 07 May 2021
Press Telegram - FinancialContent
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
